DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/92zvjh/erbb_signaling) has announced the addition of the “ErbB Signaling Pathway in Cancer Drug Pipeline Update 2014” report to their offering.
The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces the formation of receptor homo- and heterodimers and the activation of the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues (pY) within the cytoplasmic tail.
There are today 222 companies plus partners developing 356 ErbB signaling pathway targeting drugs in 1304 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 156 drugs. Erbb Signaling Pathway In Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 154 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 151 out of the 153 studied drug targets so far have been recorded with somatic mutations.
The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 37 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Drug Pipeline Update at a Glance
Includes more than 222 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.
Drug name & Synonyms
Lists commercial, generic and code names for drugs.
This Drug Pipeline Update contains 356 ErbB signaling pathway targeting drugs in development, which have a total of 1304 developmental projects in cancer. In addition there are suspended and ceased drugs.
Included ErbB signaling pathway targeting drugs are also in development for 139 other indications, where of 107 are different cancer indications.
Pipeline Breakdown According to Number of Drugs
- Marketed # 28
- Pre-registration # 6
- Phase III # 39
- Phase II # 115
- Phase I # 167
- Preclinical # 175
- No Data # 4
- Suspended # 2
- Ceased # 156
For more information visit http://www.researchandmarkets.com/research/92zvjh/erbb_signaling
This entry passed through the Full-Text RSS service — if this is your content and you’re reading it on someone else’s site, please read the FAQ at fivefilters.org/content-only/faq.php#publishers.